Small interfering‑high mobility group A2 attenuates epithelial‑mesenchymal transition in thymic cancer cells via the Wnt/β‑catenin pathway

Tan,Sheng; Chen,Jili

doi:10.3892/ol.2021.12847

Small interfering‑high mobility group A2 attenuates epithelial‑mesenchymal transition in thymic cancer cells via the Wnt/β‑catenin pathway

Authors:
- Sheng Tan
- Jili Chen
View Affiliations

Affiliations: Department of Cardiovascular Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221000, P.R. China, Department of Ophthalmology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221000, P.R. China
Published online on: June 3, 2021 https://doi.org/10.3892/ol.2021.12847
Article Number: 586
Copyright: © Tan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Thymus carcinoma is one of the thymic epithelial neoplasms with high metastasis, which does not have any good treatment at present. High mobility group A2 (HMGA2) is highly expressed in a variety of malignant tumors, such as lung cancer, colon cancer and ovarian cancer and is closely related to tumor invasion and metastasis. The present study aimed to investigate the effect and mechanism of HMGA2 on epithelial‑mesenchymal transition (EMT) in thymic cancer cells. IU‑TAB‑1, A549, HCT‑116 and 293T cells were screened by testing the protein expression level of HMGA2 though western blotting and subjected to HMGA2 interference [small interfering (si)‑HMGA2]. Cell proliferation was evaluated using the Cell Counting Kit‑8 assay. Cell migration and invasion were detected using the Transwell assay. Cell apoptosis was examined using flow cytometry and β‑catenin expression was observed by immunofluorescence. The levels of E‑cadherin, vimentin, Wnt3a, Wnt5a and β‑catenin proteins were determined by western blotting. Among the four cell lines tested, IU‑TAB‑1 cells demonstrated the highest expression of HMGA2 (P<0.05) and were hence selected for subsequent experiments. Compared with the control group (untransfected cells), si‑HMGA2 resulted in significantly decreased proliferation, migration and invasion of IU‑TAB‑1 cells, whereas apoptosis was increased (P<0.05). The protein expression of vimentin, Wnt3a, Wnt5a and β‑catenin was significantly decreased by si‑HMGA2 compared with the control group (P<0.05), whereas E‑cadherin expression was increased (P<0.05). After treatment with si‑HMGA2 in combination with Wnt/β‑catenin agonists (SKL2001) or inhibitors (XAV‑939), EMT was respectively enhanced or inhibited in IU‑TAB‑1 cells. Overall, si‑HMGA2 may attenuate EMT in thymic cancer cells and the mechanism may be related to the Wnt/β‑catenin pathway.

View Figures

View References

1	Noriyuki T: Thymic epithelial tumors. Haigan. 47:181–185. 2007. View Article : Google Scholar
2	Ji W, Feng QF, Zhou ZM, Wang M, Chen DF, Zhang HX, Xiao ZF, Wang LH and Yin WB: Treatment and prognosis analysis of 73 cases of thymic carcinoma. Chin J Radia Oncol. 15:97–100. 2006.
3	Kondo K and Monden Y: Therapy for thymic epithelial tumors: A clinical study of 1,320 patients from Japan. Ann Thorac Surg. 76:878–884; discussion 884–885. 2003. View Article : Google Scholar : PubMed/NCBI
4	Lamarca A, Moreno V and Feliu J: Thymoma and thymic carcinoma in the target therapies era. Cancer Treat Rev. 39:413–420. 2013. View Article : Google Scholar : PubMed/NCBI
5	Ozturk N, Singh I, Mehta A, Braun T and Barreto G: HMGA proteins as modulators of chromatin structure during transcriptional activation. Front Cell Dev Biol. 2:52014. View Article : Google Scholar : PubMed/NCBI
6	Narita M, Narita M, Krizhanovsky V, Nuñez S, Chicas A, Hearn SA, Myers MP and Lowe SW: A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation. Cell. 126:503–514. 2006. View Article : Google Scholar : PubMed/NCBI
7	Cleynen I and Van de Ven WJ: The HMGA proteins: A myriad of functions (Review). Int J Oncol. 32:289–305. 2008.PubMed/NCBI
8	Di Cello F, Hillion J, Hristov A, Wood LJ, Mukherjee M, Schuldenfrei A, Kowalski J, Bhattacharya R, Ashfaq R and Resar LM: HMGA2 participates in transformation in human lung cancer. Mol Cancer Res. 6:743–750. 2008. View Article : Google Scholar : PubMed/NCBI
9	Malek A, Bakhidze E, Noske A, Sers C, Aigner A, Schäfer R and Tchernitsa O: HMGA2 gene is a promising target for ovarian cancer silencing therapy. Int J Cancer. 123:348–356. 2008. View Article : Google Scholar : PubMed/NCBI
10	Huang ML, Chen CC and Chang LC: Gene expressions of HMGI-C and HMGI(Y) are associated with stage and metastasis in colorectal cancer. Int J Colorectal Dis. 24:1281–1286. 2009. View Article : Google Scholar : PubMed/NCBI
11	Hristov AC, Cope L, Reyes MD, Singh M, Iacobuzio-Donahue C, Maitra A and Resar LM: HMGA2 protein expression correlates with lymph node metastasis and increased tumor grade in pancreatic ductal adenocarcinoma. Mod Pathol. 22:43–49. 2009. View Article : Google Scholar : PubMed/NCBI
12	Bartuma H, Panagopoulos I, Collin A, Trombetta D, Domanski HA, Mandahl N and Mertens F: Expression levels of HMGA2 in adipocytic tumors correlate with morphologic and cytogenetic subgroups. Mol Cancer. 8:362009. View Article : Google Scholar : PubMed/NCBI
13	Yilmaz M and Christofori G: EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 28:15–33. 2009. View Article : Google Scholar : PubMed/NCBI
14	Singh A and Settleman J: EMT, cancer stem cells and drug resistance: An emerging axis of evil in the war on cancer. Oncogene. 29:4741–4751. 2010. View Article : Google Scholar : PubMed/NCBI
15	De Craene B and Berx G: Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 13:97–110. 2013. View Article : Google Scholar : PubMed/NCBI
16	Cheng P, Zheng CN, Ben W, Gao HJ, Niu WB, He ZB, Gao C, Zou ZJ, Ma C, Niu J, et al: Norcantharidin inhibit colon cancer cell EMT process through blocking αvβ6-ERK-ETS1 signal pathway. Chin J Curr Adv Gen Surg. 10:757–762. 2014.(In Chinese).
17	Lin Q, Zhou CR, Bai MJ, Zhu D, Chen JW, Wang HF, Li MA, Wu C, Li ZR and Huang MS: Exosome-mediated miRNA delivery promotes liver cancer EMT and metastasis. Am J Transl Res. 12:1080–1095. 2020.PubMed/NCBI
18	Zha L, Zhang J, Tang WX, Zhang N, He M, Gao Y and Wang ZW: HMGA2 elicits EMT by activating the Wnt/β-catenin pathway in gastric cancer. Dig Dis Sci. 58:724–733. 2013. View Article : Google Scholar : PubMed/NCBI
19	Eugenio Z, Gabri VDP, Gray PC and Marianna KJ: Epithelial plasticity in cancer: unmasking a microRNA network for TGF-β- and Notch-, and Wnt-mediated EMT. J Oncol. 2015:1989672015. 2015.PubMed/NCBI
20	Li Y, Ma L, Zhang YL, Jiang T, Bi GB and Sao C: Expression and clinical significance of β-catenin and axin in ovarian epithelial cell carcinoma. J Modern Integ Med. 26:2871–2873+2957. 2017.PubMed/NCBI
21	Huang XW, Cui WW, Wang BF, Song YL, Liang YJ and Dong Y: Abnormal activation of wnt/β-catenin signaling pathway in nasopharyngeal carcinoma. J Tongji Med Univ. 46:295–298. 2017.
22	Zha L, Zhang J, Tang W, Zhang N, He M, Guo Y and Wang Z: HMGA2 elicits EMT by activating the Wnt/β-catenin pathway in gastric cancer. Dig Dis Sci. 58:724–733. 2013. View Article : Google Scholar : PubMed/NCBI
23	Pan CB, Zhao XP and Zhang H: High expression of HMGA2 promotes metastasis of tongue carcinoma through EMT. The 13th National Conference on Oral and Maxillofacial Surgery.
24	Li W, Wang J, Zhang D, Zhang X, Xu J and Zhao L: MicroRNA-98 targets HMGA2 to inhibit the development of retinoblastoma through mediating Wnt/β-catenin pathway. Cancer Biomark. 25:79–88. 2019. View Article : Google Scholar : PubMed/NCBI
25	Tan S, Zhang QG, Zhang L, Liu N and Cheng Y: Expression and clinical significance of β-catenin and c-myc in invasive thymoma. J Chin Med Univ. 34:464–465. 2005.
26	Livak KJ and Schmittgen TDL: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
27	Rogalla P, Drechsler K, Kazmierczak B, Rippe V, Bonk U and Bullerdiek J: Expression of HMGI-C, a member of the high mobility group protein family, in a subset of breast cancers: Relationship to histologic grade. Mol Carcinog. 19:153–156. 1997. View Article : Google Scholar : PubMed/NCBI
28	Berner JM, Meza-Zepeda LA, Kools PF, Forus A, Schoenmakers EF, Van de Ven WJ, Fodstad O and Myklebost O: HMGIC, the gene for an architectural transcription factor, is amplified and rearranged in a subset of human sarcomas. Oncogene. 14:2935–2941. 1997. View Article : Google Scholar : PubMed/NCBI
29	Abe N, Watanabe T, Suzuki Y, Matsumoto N, Masaki T, Mori T, Sugiyama M, Chiappetta G, Fusco A and Atomi Y: An increased high-mobility group A2 expression level is associated with malignant phenotype in pancreatic exocrine tissue. Br J Cancer. 89:2104–2109. 2003. View Article : Google Scholar : PubMed/NCBI
30	Meyer B, Loeschke S, Schultze A, Weigel T, Sandkamp M, Goldmann T, Vollmer E and Bullerdiek J: HMGA2 overexpression in non-small cell lung cancer. Mol Carcinog. 46:503–511. 2007. View Article : Google Scholar : PubMed/NCBI
31	Arsianti A, Fadilah F, Bahtiar A and Tanimoto H: Phytochemical analysis and in vitro cytotoxicity of seaweed sargassum sp. Against colon HCT-116 and Lung-A549 cancer cells. Proceedings of The 18th World Congress of Basic and Clinical Pharmacology (WCP2018). pp. WCP2018Kyoto: 2018
32	Gökmen-Polar Y, Sanders KL, Goswami CP, Cano OD, Zaheer NA, Jain RK, Kesler KA, Nelson RP Jr, Vance GH, Smith D, et al: Establishment and characterization of a novel cell line derived from human thymoma AB tumor. Lab Invest. 92:1564–1573. 2012. View Article : Google Scholar
33	Lee HS, Jang HJ, Lo EM, Truong CY, Groth SS, Friedberg JS, Sugarbaker DJ and Burt BM: Povidone-iodine results in rapid killing of thymic epithelial tumour cells through cellular fixation†. Interact Cardiovasc Thorac Surg. 28:353–359. 2019. View Article : Google Scholar : PubMed/NCBI
34	Theys J, Jutten B, Habets R, Paesmans K, Groot AJ, Lambin P, Wouters BG, Lammering G and Vooijs M: E-Cadherin loss associated with EMT promotes radioresistance in human tumor cells. Radiother Oncol. 99:392–397. 2011. View Article : Google Scholar : PubMed/NCBI
35	Fransvea E, Angelotti U, Antonaci S and Giannelli G: Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology. 47:1557–1566. 2008. View Article : Google Scholar : PubMed/NCBI
36	Bussemakers MJG, van Moorselaar RJ, Giroldi LA, Ichikawa T, Isaacs JT, Takeichi M, Debruyne FM and Schalken JA: Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Res. 52:2916–2922. 1992.PubMed/NCBI
37	Fearon ER: Cancer: Context is key for E-cadherin in invasion and metastasis. Curr Biol. 29:R1140–R1142. 2019. View Article : Google Scholar : PubMed/NCBI
38	Satelli A and Li S: Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 68:3033–3046. 2011. View Article : Google Scholar : PubMed/NCBI
39	Sun S, Sun W, Xia L, Liu L, Du R, He L, Li R, Wang H and Huang C: The T-box transcription factor Brachyury promotes renal interstitial fibrosis by repressing E-cadherin expression. Cell Commun Signal. 12:762014. View Article : Google Scholar : PubMed/NCBI
40	Liu Z, Jin H, Yang S, Zhang ZY, Wen B and Zhou SB: SDC1 knockdown induces epithelial-mesenchymal transition and invasion of gallbladder cancer cells via the ERK/Snail pathway. J Inter Med Res. 8:3000605209478832020.PubMed/NCBI
41	Telford BJ, Chen A, Beetham H, Frick J, Brew TP, Gould CM, Single A, Godwin T, Simpson KJ and Guilford P: Synthetic lethal screens identify vulnerabilities in GPCR signaling and cytoskeletal organization in E-Cadherin-Deficient cell. Mol Cancer Ther. 14:1213–1223. 2015. View Article : Google Scholar : PubMed/NCBI
42	Clevers H: Wnt/β-catenin signaling in development and disease. Cell. 127:469–480. 2006. View Article : Google Scholar : PubMed/NCBI
43	Jiang D, Nai MY, Chen JZ and Wei LX: Effect of silencing HMGA2 on signal transduction pathway of Wnt/β-catenin in gastric cancer cells. World Chin J Dig. 21:1062–1069. 2013.(In Chinese). View Article : Google Scholar
44	Qin BB, Li YQ, Li XL, Lu LS, Zhang XD and Zhang MZ: Expression of Wnt/β-catenin pathway key molecules in NK/T cell lymphoma and its clinical significance. J Jilin Univ. 41:230–234. 2015.
45	Ebert MP, Fei G, Kahmann S, Müller O, Yu J, Sung JJ and Malfertheiner P: Increased beta-catenin mRNA levels and mutational alterations of the APC and beta-catenin gene are present in intestinal-type gastric cancer. Carcinogenesis. 23:87–91. 2002. View Article : Google Scholar : PubMed/NCBI
46	Shi JF and Yin F: Expression of β-catenin and hepatocyte nuclear factor-1 α in HCC and its effect on prognosis. Chin J Oncol. 36:587–591. 2014.PubMed/NCBI